Drug Database
TE

tetanus vaccine

✓ Approved

Sinovac Biotech · Vaccine · Vaccine

What is tetanus vaccine?

tetanus vaccine is a vaccine developed by Sinovac Biotech. It is approved for therapeutic indications via injectable (others).

Drug Profile

CompanySinovac Biotech
Drug ClassVaccine
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Sinovac Biotech

Therapeutic Indications

tetanus vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsTetanus✓ Approved

Related Research Articles

PubMedAAPS PharmSciTech2026-09-19

Comprehensive Stability Assessment of Squalene in a Nanoemulsion Adjuvant and the SpiN-Tec Vaccine: HPLC Quantification, Stress Testing, and Stability Studies.

Gomes Isabela Pereira IP, Rivelli Graziella Gomes GG, Bagno Flávia Fonseca FF, Hojo-Souza Natália Satchiko NS et al.

Squalene-based nanoemulsions are widely used as adjuvants in vaccine formulations, but their stability can be affected by environmental factors such as pH, oxidative stress, temperature, and light. We have produced a squalene nanoemulsion (CTVad1) to support the clinical development of new vaccines. This study aimed to develop and validate an HPLC method for squalene quantification in SpiN-Tec, a recombinant protein vaccine against COVID-19. We also aimed to evaluate the stability of the CTVad1 adjuvant and SpiN-Tec under controlled storage conditions. A reversed-phase HPLC method was developed and validated, and comprehensive forced degradation studies were performed on the raw material and SpiN-Tec under acidic, basic, oxidative, thermal, and photolytic conditions to demonstrate the stability-indicating capability of the method. Physicochemical, morphological, and biological characteristics were assessed, and stability studies of both the vaccine and the CTVad1 adjuvant were performed under accelerated and long-term conditions. The HPLC method was selective, precise, accurate, linear, and robust. Squalene raw material degraded under all tested conditions, whereas formulation in nano-sized globules improved its stability, with degradation observed only under hydrogen peroxide and light exposure. CTVad1 remained stable over time, exhibiting only minor, non-critical changes within the specification limits in both accelerated and long-term stability studies, regardless of the glass packaging used (clear or amber). In addition, the SpiN-Tec vaccine maintained its physicochemical and biological integrity under all tested conditions, with all evaluated parameters remaining within the established specification ranges. Our findings demonstrate that proper formulation, packaging, and storage conditions can preserve squalene stability in nanoemulsion-based vaccines, ensuring the quality, safety, and efficacy of the SpiN-Tec vaccine and its adjuvant throughout shelf life.

PMID 42760453
Read full article →
PubMedOcular immunology and inflammation2026-09-19

Bilateral Maculopathy in an Infant Following Measles, Mumps, Rubella, and Varicella-Zoster (MMRV) Vaccination.

Ben-Avi Ravid R, Amer Radgonde R

To report on the long-term clinical outcome of a healthy infant who presented with posterior uveitis following the administration of the combined measles, mumps, rubella, and varicella (MMRV) vaccine. Descriptive case report. A 13-month-old infant presented with bilateral visual loss two weeks after receiving the MMRV vaccine. Ophthalmic examination revealed bilateral retinitis and retinal vasculitis with exudative retinal detachment. Extensive infectious work-up was conducted including serologic exams and PCR testing of blood, aqueous humor, cerebrospinal fluid and urine. Serological tests for measles yielded positive IgM and IgG titers. PCR testing for measles in the aqueous humor and urine was negative. Neurologic assessment and neuroimaging were unremarkable, excluding central nervous system involvement. Empiric systemic antiviral and corticosteroid therapy was initiated. Gradual resolution of posterior uveitis ensued, culminating in bilateral macular scars. Over a six-year follow-up period, the patient demonstrated stable ocular findings with no evidence of recurrent inflammation or systemic autoimmune disease. Final visual acuity was 6/9 in each eye. This case represents a rare occurrence of non-necrotizing retinitis following MMRV vaccination. To our knowledge, this is the first report describing the sequential OCT characteristics of presumed measles vaccine-associated retinitis. The prolonged follow-up period supports the absence of an alternative etiology and provides valuable insight into the long-term course and visual prognosis of vaccine-associated retinopathy.

PMID 42760840
Read full article →
PubMedMedScience2026-09-19

Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.

Zhao Zixuan Z, Du Xinyu X, Gao Xiaoliang X, Zhao Sheng S et al.

Gastrointestinal tumors are characterized by high global incidence and mortality rates. Although immune checkpoint inhibitors (ICIs) have achieved breakthroughs in some of these cancers, their overall response rate remains low. Neoantigen cancer vaccines have emerged as a promising new strategy for immunotherapy in gastrointestinal tumors due to their high specificity and strong immunogenicity. These vaccines effectively activate specific T-cell immunity and can produce synergistic effects when combined with ICIs. Various vaccine platforms offer distinct advantages, and clinical trials have shown encouraging potential in inducing immune responses and extending progression-free survival. Meanwhile, current challenges and future directions cannot be ignored. Key challenges primarily involve the accuracy of neoantigen prediction, tumor heterogeneity, and optimal treatment timing. Future directions include artificial intelligence (AI)-assisted multi-omics screening, the development of universal vaccines, optimization of novel delivery systems, and multimodal combination strategies. These advances are expected to promote the application of neoantigen cancer vaccines in postoperative recurrence prevention and early-stage treatment, ultimately moving toward personalized precision immunotherapy. This article systematically reviews the clinical progress and prospects of neoantigen cancer vaccines in treating gastrointestinal tumors, aiming to provide insights for immunotherapy in this field and offer new perspectives for further optimization of such vaccines.

PMID 42760419
Read full article →
PubMedVaccine2026-09-18

Promoting a personalized vaccine information website through social media and local outreach: a dissemination and implementation study.

Forr Amanda A, Salmon Daniel A DA, Markalanda Shaniya H SH, Joseph Ann A et al.

Vaccine hesitancy is a major public health problem, with social media playing a crucial role in the spread of reliable vaccine information, as well as misinformation and disinformation. LetsTalkShots is a website that offers tailored, evidence-based vaccine information including personal narratives, credible sources, and animation. We compared the cost of promoting LetsTalkShots through outreach efforts of five local public health departments versus a paid social media campaign targeting the same five communities. Social media ads drove traffic at a low cost per click, though local outreach efforts achieved a lower cost per completed question set at LetsTalkShots.org. Content engagement was particularly low for COVID-related topics, perhaps due to pandemic fatigue or negative perceptions of the COVID vaccine. Engagement was highest for RSV content, perhaps because it was a new vaccine about which people were seeking credible, relevant information. Social media and localized outreach can aid vaccine communication efforts, especially when content is relevant and timely.

PMID 42759248
Read full article →
PubMedFrontiers in immunology2026-09-18

An mRNA-based FimH nanoparticle vaccine against uropathogenic Escherichia coli confers protection in a mouse model of recurrent urinary tract infection.

Roier Sandro S, Devant Jessica M JM, Hibbing Michael E ME, Möbes Annette A et al.

Increasing antimicrobial resistance and the high health and economic burden of frequent, recurring urinary tract infections (rUTIs) drive the need for an efficacious UTI vaccine. Most UTIs are caused by uropathogenic E. coli (UPEC) expressing the virulence factor FimH, which mediates bladder colonisation. We have developed a lipid nanoparticle (LNP) mRNA vaccine, FimHDG-Ferritin, as a UPEC vaccine candidate. FimHDG-Ferritin mRNA constructs were introduced into HeLa cells through mRNA-transfection to assess the generation of immune-accessible protein nanoparticles (PNPs) in vitro by native polyacrylamide gel electrophoresis and negative stain electron microscopy. Following this, induction of humoral and cellular responses were evaluated in female BALB/c AnNRj mice and Wistar rats following either 2 or 3 intramuscular administrations of the FimHDG-Ferritin mRNA vaccine. Finally, protective efficacy was assessed in a clinically relevant mouse model of rUTI. In vitro PNP formation of the FimHDG-Ferritin fusion protein with intact functional epitopes was confirmed. Immunogenicity was demonstrated in mice and rats; equivalent functional antibody levels were raised against homologous and heterologous UPEC strains. In a rUTI mouse model, FimHDG-Ferritin mRNA vaccine administration induced the highest levels of functional antibodies among protein subunit comparators and significantly reduced bladder bacterial load versus negative controls. These preclinical data in rodents establish the FimHDG-Ferritin mRNA vaccine as a protective candidate vaccine to prevent UTI caused by UPEC, supporting consideration for phase 1 clinical evaluation.

PMID 42756059
Read full article →
PubMedBiomedica : revista del Instituto Nacional de Salud2026-09-18

Correct vaccination practices begin with proper education: The effect of professional training on vaccine advocacy among healthcare professionals.

Tiryaki Öznur Ö

Healthcare professionals, particularly midwives and nurses, have played a fundamental role in global immunization efforts by acting as the primary providers responsible for vaccine administration. This study aims to determine whether there is a statistically significant difference in Childhood Vaccination Advocacy Scale scores before and after vaccine advocacy awareness training. Data were collected using a questionnaire on demographic characteristics and knowledge regarding vaccine administration, developed by the researcher in accordance with the literature, as well as the Vaccine Advocacy Scale for Childhood Vaccines. This research was designed as a single-group, pre-test and post-test quasi-experimental study. Pre-test and post-test scores were compared using the Wilcoxon signed-rank test. A significance level of p < 0.05 was considered statistically significant. The study was conducted with 249 midwives and/or nurses. The mean age of the participants was 39.40 ± 7.43 years, with an average of 18.01 ± 7.99 years of profesional experience. The mean total score on the Vaccine Advocacy Scale for Childhood Vaccines was 45.19 ± 2.85 before the training and 46.95 ± 1.99 after the training. A Wilcoxon signed-rank test revealed that the increase in post-training scores was statistically significant (p = 0.000). The findings indicate that participants had relatively high levels of vaccine advocacy even prior to the training. However, the statistically significant improvement in scores post-training clearly demonstrates the effectiveness of the educational intervention.

PMID 42757794
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about tetanus vaccine